<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>2099857</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Moreno, S</dc:author>
<dc:author>López Bernaldo de Quirós, J C</dc:author>
<dc:author>Berenguer, J</dc:author>
<dc:author>Garau, X</dc:author>
<dc:author>Bouza, E</dc:author>
<dc:author>Muñoz, P</dc:author>
<dc:author>More, J</dc:author>
<dc:description xml:lang="en">We have evaluated the efficacy of fluconazole, 50 mg/day for 2 weeks, to treat oropharyngeal candidiasis in immunologically compromised patients. There were overall 27 patients, 25 of which were HIV+ and 2 had neutropenia. The rate of clinical response at the end of therapy, and one week and one month afterwards were 96%, 76% and 64%, respectively. The microbiological eradication was achieved in 36% of patients. The tolerance of the drug was satisfactory, although in 3 cases features of hepatic toxicity were detected. The convenience, good tolerance and clinical efficacy of fluconazole make it the therapy of choice for oropharyngeal candidiasis in immunologically compromised patients.</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>1990 Nov </dc:date>
<dc:title xml:lang="es">Estudio multicéntrico de fluconazol en el tratamiento de la candidiasis orofaríngea en pacientes inmunodeprimidos.</dc:title>
<dc:title xml:lang="en">[Multicenter study of fluconazole in the treatment of oropharyngeal candidiasis in immunodepressed patients].</dc:title>
<dc:publisher>Enfermedades infecciosas y microbiologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
